These data encouraged us to replenish the lack of preclinical information with transgenic models for PDA pathology, using Ela-myc mice as a different transgenic pancreatic tumor model from the previously published k-ras model [21]. This evidence concerns the gene MYC and Patent ductus arteriosus.